The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma ...

Binod Dhakal, MD, MS, discusses how the efficacy results observed with ciltacabtagene autoleucel in the CARTITUDE-4 trial compare with other therapies that are used for the treatment of ...

Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...

Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with ...

Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ineligible multiple myeloma patients. No significant difference in serious adverse ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

They were driven by new pharmaceutical launches (up 67.1% to €727 million), including Altuviiio, used to treat haemophilia, Tzield - for type 1 diabetes -, Sarclisa (multiple myeloma) and Rezurock, ...